Halozyme Therapeutics Inc (HALO)
Debt-to-equity ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | 1,499,250 | 1,497,620 | 1,496,000 | 1,494,380 | 1,492,770 | 1,491,160 | — | — | 787,255 | — | — | — | 0 | — | — | — | 383,045 | — | — | — |
| Total stockholders’ equity | US$ in thousands | 83,808 | 249,181 | 151,033 | 65,850 | 169,798 | 96,991 | 293,171 | 260,256 | 196,953 | 281,674 | 119,746 | 67,595 | 151,047 | 98,988 | 105,577 | 58,042 | 91,765 | 245,353 | 260,052 | 260,047 |
| Debt-to-equity ratio | 17.89 | 6.01 | 9.91 | 22.69 | 8.79 | 15.37 | 0.00 | 0.00 | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.17 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $1,499,250K ÷ $83,808K
= 17.89
The debt-to-equity ratio of Halozyme Therapeutics Inc. has shown fluctuations over the past eight quarters. The ratio was at its highest in Q1 2023 at 22.69, indicating that the company had a higher proportion of debt relative to its equity during that period. This was followed by a significant decrease in Q2 2023 to a ratio of 9.91, showing an improvement in the company's debt levels compared to the previous quarter.
The trend continued in Q3 2023, with a further decrease in the debt-to-equity ratio to 6.01, suggesting a continued reduction in the company's reliance on debt financing. However, in Q4 2023, the ratio increased to 17.89, indicating a higher level of debt relative to equity compared to the previous quarter.
Overall, it is important to note that a lower debt-to-equity ratio is generally considered favorable as it suggests lower financial risk and a more stable capital structure. Halozyme Therapeutics Inc. appears to have experienced fluctuations in its debt-to-equity ratio, and it would be advisable for the company to closely monitor and manage its debt levels to maintain a healthy balance between debt and equity financing.
Peer comparison
Dec 31, 2023